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Background: Bipolar disorder (BD) is a complex psychiatric phenotype with a high heritability and a multifactorial
etiology. Multisite collaborative efforts using genome-wide association studies (GWAS) have identified only a portion
of DNA sequence-based risk factors in BD. In addition to predisposing DNA sequence variants, epigenetic misregulation
may play an etiological role in BD and account for monozygotic twin discordance, parental origin effects, and
fluctuating course of BD. In this study, we investigated DNA methylation of the brain-derived neurotrophic factor
(BDNF) gene in BD.
Methods: Fifty participants with BD were compared to the same number of age- and sex-matched controls for
DNA methylation differences at BDNF promoters 3 and 5. DNA methylation reads were obtained using a mass
spectrophotometer for 64 cytosine-guanine (CpG) sites in 36 CpG ‘units’ across three amplicons of BDNF promoters
3 and 5.
Results and Discussion: Methylation fractions differed between BD participants and controls for 11 of 36 CpG
units. Five CpG units, mostly in promoter 5, remained significant after false discovery rate correction (FDR)
(p values ≤ 0.004) with medium to large effect sizes (Cohen's d ≥ 0.61). Several of the significant CpGs
overlapped with or were immediately adjacent to transcription factor binding sites (TFBSs) - including two of
the FDR-significant CpG units in promoter 5. For the CpGs in promoter 3, there was a positive and significant
correlation between age at sample collection and DNA methylation fraction (rho = 0.56, p = 2.8 ×10−5) in BD
cases, but not in controls. Statistically significant differences in mean methylation fraction at 5/36 CpG units
(after FDR), some at or immediately adjacent to TFBSs, suggest possible relevance for the current findings to
BD etiopathogenesis. The positive correlation between age and methylation seen in promoter 3 is consistent
with age-related decline in BDNF expression previously reported. Future studies should provide more exhaustive
epigenetic study of the BDNF locus to better characterize the relationship between BDNF methylation differences
and BD.
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Bipolar disorder (BD) is a major psychiatric illness with
a complex multifactorial etiology. Twin and adoption studies
underscore the importance of inherited factors, and associ-
ation studies, including genome-wide association studies by
large consortia, have reported some replicable loci, notably
CACNA1C, ODZ4, and NCAN (Cichon et al. 2011; Psy-
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tory in a close relative is still the best genetic prediction
method for BD, and other molecular methods may be
helpful to address the genetics of non-Mendelian disor-
ders (Craddock and Sklar 2013; Schulze 2010).
In addition to genetic studies, discordance for BD in
monozygotic (MZ) twins (Bertelsen et al. 1977; Sklar et al.
2002; McGuffin et al. 2003; Kieseppa et al. 2004) invites
speculation about environmental risk factors. Evidence is
suggestive of a role for environment in the genesis and
course of BD (Serretti and Mandelli 2008). Prospective
studies implicate psychosocial and other environmentaln Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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et al. 2011). Other data indicates that at least one third of
adults with a BD diagnosis report childhood trauma,
which is associated with more difficult course of illness
(Leverich and Post 2006). Yet the specific role of environ-
ment remains unclear. Stressful life events are associated
with BD, but robust evidence of a cause-effect relationship
is lacking (Miklowitz and Chang 2008). And overall, envir-
onment plays a lesser role in the risk for developing the
illness (McGuffin et al. 2003). Thus, despite the significant
effort, much remains to be understood about the genetic
and environmental basis of BD.
In recent years, epigenetic factors have become an av-
enue of investigation with some promise (Labrie et al.
2012), with the complex epigenetic regulation of Bdnf
showing relevance to psychiatric disorders and environ-
ment (Boulle et al. 2012). Numerous clinical and epidemio-
logical features of BD can be explained by epigenetic
misregulation. Epigenetics refers to regulation of various
genomic functions that are controlled by heritable, partially
stable modifications in DNA methylation and/or chroma-
tin structure (Henikoff and Matzke 1997). Epigenetic stud-
ies in twins have detected a large degree of MZ co-twin
DNA methylation variation (Petronis et al. 2003; Kaminsky
et al. 2009), which may contribute to the MZ twin discord-
ance observed in BD. Putative epigenetic misregulation is
also consistent with variable age of onset, fluctuating
clinical course with exacerbations and remissions, peaks
of susceptibility coinciding with hormonal changes,
parent-of-origin effects, and sexual dimorphism (Arnold
et al. 2003).
Epigenetics gives additional framework for understanding
the function of genome sequence and genetic complexity.
Ambiguous genetic results on complex disease phenotypes
could be more salient if considered in an epigenomic con-
text (Feinberg 2010). In aggregate, such findings have led
to the notion that epigenetic factors may be relevant to
complex non-Mendelian phenotypes like BD (Labrie et al.
2012; Petronis 2003) and may account for a fraction of the
‘missing heritability’ of complex traits (Maher 2008).
Several lines of evidence link brain-derived neuro-
trophic factor (BDNF) to BD. Serum BDNF levels are
reduced in depression (Molendijk et al. 2013), euthymic
BD (Monteleone et al. 2008), acute mania (Machado-Vieira
et al. 2007; Tramontina et al. 2009), and bipolar depression
(Fernandes et al. 2009) and are lower with longer duration
of illness (Kauer-Sant'Anna et al. 2009). A meta-regression
has confirmed that serum/plasma BDNF levels are consist-
ently reduced during manic and depressive episodes and
are restored to normal levels in subjects treated for acute
mania (n = 1,113 subjects) across 13 studies (Fernandes
et al. 2011). From genetics reports, polymorphisms within
the BDNF gene have been studied in BD (Neves-Pereira
et al. 2002; Sklar et al. 2002). There is a frequently citedassociation between BD and the SNP rs6265, also known
as the Val66Met variant. Association of SNP rs6265 has
been repeatedly shown with BD and was statistically sig-
nificant in a meta-analysis of 14 studies comprising of
4,248 cases, 7,080 controls, and 858 nuclear families
(Fan and Sklar 2008). More recently, rs6265 Met allele
carriers were observed to have different serum BDNF
profiles during a period of treatment than Val allele ho-
mozygotes (Grande et al. 2013).
A limited number of studies have been conducted to
investigate DNA modifications at BDNF in BD, and most
were done on postmortem brain tissue. Among them, a
comprehensive study showed cytosine-guanine dinucleo-
tide (CpG) DNA methylation variation in BD patients in
proximity of the BDNF SNP rs6265; exonic CpG methy-
lation was associated with the valine variant of rs6265 in
a sample of 105 postmortem brains (Mill et al. 2008). In
another study, Rao et al. (2012) demonstrated increased
methylation of BDNF promoter 1 in frontal cortex tissue
in ten BD brains compared to ten age-matched controls
(p < 0.05). Hypermethylation at BDNF promoter 1 in
peripheral blood monocyte DNA has also been reported
in 16 participants with Bipolar II Disorder (BD-II) (p < 0.01)
but not for 16 participants with Bipolar I Disorder (BD-I)
when compared to controls; the investigators also ob-
served that lithium and valproate reduce promoter 1 DNA
methylation (D'Addario et al. 2012).
The evidence reviewed above suggests a putative role
for the BDNF locus in BD. Our aim was to characterize
epigenetic regulation of BDNF in peripheral blood, and
our hypothesis was that BD patients exhibit BDNF pro-
moter methylation differences compared to controls.
Methods
Subjects
Participants consisted of 50 randomly selected BD cases
and 50 unrelated healthy controls matched for age and
sex from a larger sample (n = 452 BD cases) as previously
described (Scott et al. 2009; Psychiatric GWAS Consor-
tium Bipolar Disorder Working Group 2011). Inclusion
criteria were as follows: (a) diagnosed with DSM-IV or
ICD-10 BD-I or II, (b) age 18 years old or above, and (c)
Caucasian, of Northern and Western European origin. Ex-
clusion criteria includes the following: (a) diagnosis of
intravenous drug dependence or reported use of intraven-
ous drugs, (b) evidence of mental retardation, (c) related
to an individual already in the study, (d) manias that only
ever occurred in relation to or as a result of alcohol or
substance abuse or dependence, medications, and/or med-
ical illness, and (e) had mood-incongruent psychotic
symptoms. BD diagnoses were established according to
DSM-IV or ICD-10 criteria, using the computerized
algorithm (CATEGO) for the SCAN 2.1 interview
(WHO) (Celik 2003). Our investigation was completed in
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approved by the Research Ethics Board of the Centre for
Addiction and Mental Health.
Clinical and demographic characteristics
Fifty randomly selected cases were included. All cases se-
lected had BD-I; none of the 50 randomly selected cases
had BD-II. All participants were of northern European an-
cestry. They were equal with equal numbers of males and
females. Cases and controls were matched for sex and age.
Mean ages at phlebotomy (SD) for cases and controls
were 45.3 (12.4) and 45.4 (12.4) years, respectively.
Genomic DNA extraction
Venous blood was collected in Toronto at the Centre for
Addiction and Mental Health and preserved in ethylene-
diaminetetraacetic acid (1.8 mg EDTA/mL of blood).
DNA was extracted using a high salt method (Lahiri and
Nurnberger 1991). Quantity and quality of genomic
DNA was estimated on nanodrop spectrophotometer
(Nanodrop Products, Wilmington, DE, USA), and gen-
omic DNA with 260/280 ratio >1.8 and 260/230 >1.9
was taken for downstream analysis.
Estimation of BDNF promoter DNA methylation
BDNF sequence (AF411339.1) was used to map different
known CpG promoters within the gene (Figure 1); two
methods were used. First, the CSHL human promoter
mapping using CpG islands (CpGpromoter) (Ioshikhes
and Zhang 2000) enabled mapping of human promoters
using Gardiner-Garden and Frommer's definition of CpG
islands (Gardiner-Garden and Frommer 1987) (http://
rulai.cshl.org/tools/CpG_promoter). CpGpromoter indi-
cated CpG islands related to promoters at three regions
of AF411339.1. Second is the BIMAS Promoter ScanFigure 1 Graphical overview at BDNF gene. The BDNF gene structure a
(2007). Arrow on the top shows the direction of BDNF transcript; exons (gr
(black) are mapped on NCBI accession number AF411339.1. CpG island we
uk/Tools/seqstats/emboss_cpgplot/). Number of CpG dinucleotides in each(Center for Information Technology, NIH, http://www-
bimas.cit.nih.gov/molbio/proscan/), which uses PROSCAN
1.7 to predict promoters based on scoring homologies
with eukaryote Pol II sequences. BIMAS corroborated the
three CpG island promoters noted with CpGpromoter,
which correspond to BDNF promoters 1, 3, and 5 of the
nine promoters described by Pruunsild et al. (2007) (see
Figure 1).
Bisulfite conversion was performed on 500 ng of gen-
omic DNA using the QiagenEpiTect Kit, Hilden, Germany,
according to the manufacturer’s protocol. Primers were
then designed on these promoters, and in total, three
amplicons were generated covering 30 CpG sites at pro-
moter 3 and 42 CpG sites at promoter 5.
Multiple attempts and different primer pairs in our
hands failed to amplify any region at promoter 1. Bisulfite
primers and polymerase chain reaction (PCR) amplifica-
tion conditions are stated in Additional file 1: Table S1.
The amplified fragments were analyzed on a MassAR-
RAY platform (Sequenom, San Diego, CA, USA) at the
Clinical Genomics Centre in Toronto (http://www.clini-
calgenomics.ca/). Locus-specific PCR amplification was
performed with the T7-promoter tagged primers, where
the latter was used to generate in vitro transcription on
the amplified fragments. These transcripts were then sub-
jected to enzymatic RNA base pair cleavage. The resulting
fragments differ in size and mass depending on the se-
quence changes generated through bisulfite treatment.
The fragment mass was determined by matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry; then, EpiTYPER software converted
MALDI-TOF (Ehrich et al. 2005) values to quantitative
percent of CpG dinucleotide methylation. The method
reads small DNA fragments for mass-to-charge ratio, and
these small reads may map to multiple CpG sites on thend promoter locations are adopted from the study of Pruunsild et al.
een), CpG islands (cyan), and investigated regions for DNA methylation
re detected by CpGPlot using default parameters (http://www.ebi.ac.
amplicons is shown as lollipops on the lower panel.
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one measured value. The resulting analytic units are called
CpG units which consist of a single CpG site or a combin-
ation of two or three CpG sites. Methylation measures
were performed in triplicate expressed as a methylation
fraction (range 0 to 1) for each CpG.
Additional exploratory analyses of BDNF promoter
methylation by BDNF rs6265 (i.e., Val66Met) genotype
were conducted to investigate possible interaction ef-
fects. Genotyping with Illumina HumanHap550 Bead-
Chip, Illumina Inc., San Diego, CA, USA, and quality
control methods were as previously described (Scott
et al. 2009). Specifically, individual CpG unit methylation
was tested for association with BD in two genotype
groups: A (rare) allele carriers consisting of AG and AA
genotypes and G (common) allele homozygotes.
Statistical analysis
Univariate statistics were performed for demographic
and clinical characteristics of BD patients and control
individuals. The means of the triplicate methylation frac-
tions (MMFs) were examined, only the readouts with
standard deviations < 0.15; therefore, 8 of 72 CpG sites
were excluded for a total of 64 CpGs comprising 36
CpG units. Since 15 of 36 CpG units had significant dif-
ferences in homogeneity of variances, the nonparametric
Mann–Whitney test was used for differences in mean
methylation fractions (in both Table 1 and Additional file
2: Table S2). We tested age and sex for association with
DNA methylation and corrected for multiple testing
with false discovery rate (FDR) (Benajmini and Hochberg
1995) for 36 CpG units, yielding a significance threshold
of alpha = 0.004.
Results
Regional CpG promoter methylation
We examined DNA methylation for each CpG promoter
region using the average of all CpG units mean methyla-
tion fractions (MMFs) in a BDNF region that we studied,
in this case, the amplicons that were assayed. A signifi-
cant difference in BDNF methylation between cases and
controls for region/amplicon D3 (Z = −2.185, p = 0.029)
was noted. The other two regions exhibited no signifi-
cant case–control differences in DNA methylation, D2a
(Z = −1.915, p = 0.055) or D5 (Z = −0.0417, 0.677). This
was also evident at the individual CpG level of DNA
methylation analysis (below), where the majority of sig-
nificant CpG units were in region D3.
Methylation of individual CpGs
D2a amplicon
Individual CpG units with nominal (p < 0.05) case–control
differences in MMF were CpG 17 (Z = −2.33, p = 0.02),
CpG 22,23 (Z = −2.094, p = 0.036), and CpG 3 (Z = −3.315,p= 0.001. Cases were more methylated than controls; of
these, only CpG 3 passed FDR correction).
D3 amplicon
Several CpG units demonstrated significance within this
region. Four CpG units survived FDR, including CpG
11,12,13 (Z = −2.889, p = 0.004), CpG 15,16,17 (Z = −2.993,
p = 0.003), CpG 18 (Z = −3.179, p = 0.001), and CpG
22,23,8 (Z = −3.8, p = 0.001). Two CpG units had nominally
significant case–control differences in methylation, CpG
14 (Z = −2.37, p = 0.018) and 9,10 (Z = −2.017, p = 0.044);
at each of the significant CpG units, cases had higher
MMFs than controls.
D5 amplicon
Differences in methylation were nominally significant at
CpG units 11,12,13 (Z = −1.962, p = 0.05), 16 (Z = −2.119,
p = 0.034), and 17,18,19 (Z = −2.447, p = 0.014); none
were significant after the FDR correction.
For CpG units which remained significant after FDR,
differences in MMF ranged from 0.007 to 0.022, with
Cohen's d ranging from 0.61 to 0.91. See Table 1.
TFBS mapping
Next, we looked for the transcription factor binding sites
(TFBSs) that are in proximity to significant individual
CpG results. For this, we mapped the DNA sequences of
the three BDNF amplicons for their TFBSs, using the
transcription factor binding profile database JASPAR
(http://jaspar.genereg.net/), and investigated the distance
between CpGs having at least nominally significant
group differences in DNA methylation and the nearest
TFBS. At the D2a amplicon, CpG unit 17 showed GATA
binding protein 2 and 3 (GATA2 and GATA3) TFBSs.
For amplicon D3, CpG unit 15,16,17 showed a complete
overlap with an AP-2 alpha (activating enhancer binding
protein 2 alpha) (TFAP2A) (Comb and Goodman 1990)
binding site, and another TFAP2A site was within 3 bp
downstream of CpG unit 22,23,8. Similarly, within
amplicon D5, three TFBSs were at or within 15bp of
CpGs: a TFAP2A site spans CpG unit 11,12,13; a mye-
loid zinc finger 1 (MZF1) TFBS was at CpG unit
17,18,19, and a nuclear factor-kappa B (NFKB1) (Rau
et al. 2012) TFBS was 15 bp downstream of CpG
17,18,19. The TFBSs above - GATA2, GATA3, TFAP2A,
MZF1, and NFKB1 - are all expressed in brain and white
blood cells.
Age, sex, and BDNF methylation
The D2a amplicon showed a positive correlation be-
tween age at sample collection and MMF (rho = 0.56,
p = 2.80 × 10−5) in BD cases, but no correlation was
observed in controls (rho = 0.17, p = 0.25) (Figure 2).
In contrast, no correlation of DNA methylation with
Table 1 Mean methylation fractions for BDNF CpG units in bipolar disorder versus controls
Amplicon CpG unit BP MMF (SD) Controls MMF (SD) Z Asymp. sig. Cohen's d
D2a 1, 2 0.354 (0.077) 0.335 (0.067) −1.712 0.087
11, 26 0.156 (0.025) 0.159 (0.038) −0.061 0.951
12, 13, 14 0.301 (0.030) 0.289 (0.034) −1.864 0.062
15 0.103 (0.022) 0.100 (0.026) −0.682 0.495
16 0.086 (0.012) 0.082 (0.015) 1.797 0.072
17 0.122 (0.032) 0.116 (0.015) −2.33 0.02*
18, 19, 20 0.242 (0.032) 0.232 (0.035) −1.789 0.072
21 0.128 (0.014) 0.126 (0.023) −0.449 0.654
22, 23 0.275 (0.018) 0.260 (0.023) −2.094 0.036*
24 0.089 (0.011) 0.086 (0.028) −1.217 0.224
27, 28, 29, 30 0.246 (0.031) 0.238 (0.014) −1.284 0.199
3 0.355 (0.034) 0.333 (0.032) −3.315 0.001** 0.680
4 0.054 (0.025) 0.048 (0.031) −1.054 0.292
5, 6 0.279 (0.047) 0.274 (0.022) −0.733 0.464
9, 10 0.254 (0.034) 0.255 (0.038) −0.256 0.798
D3 11, 12, 13 0.227 (0.014) 0.217 (0.019) −2.889 0.004** 0.610
14 0.085 (0.011) 0.079 (0.017) −2.37 0.018*
15, 16, 17 0.181 (0.016) 0.163 (0.027) −2.993 0.003** 0.840
18 0.068 (0.012) 0.061 (0.011) −3.179 0.001** 0.610
19 0.055 (0.011) 0.056 (0.012) −0.157 0.875
2, 3, 4 0.284 (0.019) 0.282 (0.020) −0.484 0.628
20 0.480 (0.068) 0.504 (0.101) −0.728 0.466
21 0.021 (0.008) 0.021 (0.015) −0.728 0.466
22, 23, 8 0.136 (0.008) 0.126 (0.014) −3.8 <0.001** 0.910
5, 6 0.316 (0.029) 0.302 (0.054) −0.601 0.548
7 0.068 (0.011) 0.066 ()0.016 −0.799 0.424
9, 10 0.069 (0.009) 0.066 (0.012) −2.017 0.044*
D5 11, 12, 13 0.233 (0.030) 0.220 −1.962 0.05*
14 0.065 (0.014) 0.063 −0.853 0.394
15 0.253 (0.085) 0.253 −0.155 0.877
16 0.093 (0.022) 0.083 −2.119 0.034*
17, 18, 19 0.172 (0.017) 0.160 −2.447 0.014*
4, 5 0.168 (0.097) 0.200 −1.09 0.276
6 0.056 (0.017) 0.057 −0.391 0.696
7, 8 0.205 (0.021) 0.197 1.671 0.095
9 0.061 (0.048) 0.074 −1.35 0.177
*Significant at alpha = 0.05; **significant after FDR, alpha = 0.004; BP, bipolar disorder. MMF, mean methylation; d, effect size; Z, Mann Whitney U test statistic.
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on DNA methylation were observed in any of the three
amplicons (see Figure 2).
In summary, we found five CpG units in BDNF pro-
moters with MMFs differing between BD and controls,
predominantly in the D3 amplicon. We also observed
positive correlation between age and MMF in D2a ampli-
con of promoter 3, significant in cases but not controls.When testing for genotype group differences at indi-
vidual CpG unit methylation sites, six CpG units were
nominally significant (two in each of the three ampli-
cons) at alpha = 0.05. With a slightly more stringent
threshold of alpha = 0.01, six other CpG units remained
significant, five of which were in amplicon D3. The pre-
ponderance of most significant post hoc methylation find-
ings were with the rs6265 G or Val homozygotes at CpG
Figure 2 Correlation between age and CpG unit methylation.
Methylation at amplicon D2a is correlated with age in bipolar cases
but not in controls. Black, BP cases (rho = 0.56, p = 2.80 × 10−5).
Gray, controls (rho = 0.17, p = 0.25)
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trol analysis (D2, CpG unit 3; D3, CpG units 11,12,13;
15,16,17; 22,23,8). See Additional file 2: Table S2.
Discussion
We examined three amplicons over two BDNF CpG
promoters in 50 BD I participants and 50 age- and sex-
matched controls. Of 36 CpG units, 6 CpG units differed
nominally in MMF between cases and controls; 5 CpG
units’ MMFs, mostly in amplicon D3 (promoter 5),
remained significant following FDR. Effect sizes were
medium to large (0.61 to 0.91) at CpG units significant
after FDR, while absolute differences in methylation
fraction were small (0.002 to 0.022). We noted that sev-
eral of these significant CpG units were at or in the
immediate vicinity of TFBSs. We also observed a statisti-
cally significant correlation between the participant's age
and DNA methylation for D2a (promoter 3) in the cases;
however no correlation was found for the controls. The
majority of findings published to date have been on
other promoters, unlike ours, which focused on pro-
moters 3 and 5. The age promoter 3 methylation correl-
ation was less strong when cases and controls were
pooled (rho = 0.353; p = 0.00036) but still significant.
Earlier investigations have examined BDNF methyla-
tion in affected brain tissues. In postmortem tissue from
Wernicke's area, four CpG dinucleotides in the BDNF
promoter 4 area had elevated methylation in suicide
cases compared to controls (Keller et al. 2010). Another
postmortem brain study reported BDNF promoter hyper-
methylation in frontal cortex tissue in BD (Rao et al.
2012), in accord with the same group's previous finding
of reduced BDNF mRNA in Brodmann area 9 of BDbrains (Kim et al. 2010). The investigators examined sev-
eral loci in the same region in BD and Alzheimer's disease,
including 81 CpG sites in BDNF promoter 1. Our findings
differ not only in the tissue of interest but also in the
promoters assayed.
A limited number of studies have focused the DNA
methylation analysis at BDNF promoters using blood-
derived DNA in psychiatric or addiction patients. For
example, maternal prenatal smoking has been shown to
increase methylation of BDNF exon 6 in adolescent off-
spring (Toledo-Rodriguez et al. 2010). In major psych-
osis patients, BDNF promoter 1 was hypermethylated in
peripheral blood monocytes for BD-II but not for BD-I;
again, we did not assay promoter 1 and have no methy-
lation data on BP-II for the current report. Influence
from medication has also been reported: antidepressants
were associated with increased methylation, while mood
stabilizers were associated with reduced methylation
(D'Addario et al. 2012). The CpG units that were signifi-
cant in our investigation had cases with higher MMFs
than controls. BDNF promoter 1 DNA methylation sig-
nals were also reported for unipolar major depressive
disorder patients; a small number of CpG units demon-
strated several fold increase or decrease in methylation
in cases versus controls by mass spectrometry and sub-
sequent hierarchical cluster analysis, generating p values
smaller than 10−11 (Fuchikami et al. 2011). Other studies
have recently demonstrated higher degrees of methyla-
tion in the BDNF region to be associated with other
mood-related phenotypes such as poststroke depres-
sion (Kim et al. 2013) and antidepressant response
(Tadić et al. 2013).
Association of age with DNA methylation, including
promoter methylation, is well documented (Jaenisch and
Bird 2003; Kwabi-Addo et al. 2007; Vasilatos et al. 2009;
Liu et al. 2010). Human prefrontal cortex genomic DNA
has age-related dynamic methylation at several gene pro-
moters (Numata et al. 2012). DNA methylation in blood
cells was also reported to correlate with age and local se-
quence features (Langevin et al. 2011). Some studies con-
flict or suggest that methylation-age associations are tissue-
and locus-dependent (Eckhardt et al. 2006; Heijmans et al.
2007). We noted a positive correlation between age and
CpG methylation in BDNF promoter 3, only for the BD
cases. Serum BDNF concentrations have been negatively
correlated with age (Kauer-Sant’Anna et al. 2009). Taken
together, such findings suggest that a reduction in BDNF
expression with age might be associated with increased
methylation observed at promoter 3.
Some limitations in the present study require acknow-
ledgement. First, we opted for an agnostic in silico ap-
proach for CpG promoter detection with CpGpromoter
and BIMAS and investigated a few promoters. There are
nine known BDNF promoters. We created primers for
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and immediately below), one of which (promoter 1) was
not completed due to technical issues. Promoters other
than 1, 3, and 5 did not score as highly on the in silico
scans.
Our laboratory method for DNA methylation investi-
gation exploits mass spectrometry, which is a precise
technique that detects very small DNA methylation dif-
ferences (to 14 kDa). This highly sensitive method was
used to assay candidate CpG units from peripheral blood
DNA and hence requires validation for DNA methyla-
tion differences in the affected tissue, i.e., postmortem
brain. While some evidence points to differences between
blood, cortical, and cerebellar methylation for several neu-
rodevelopmental genes, including BDNF (Davies et al.
2012), generally, BDNF methylation shows consistency
across brain and blood (Ikegame et al. 2013). Still, a grow-
ing number of analyses based on leukocyte-derived DNA
methylation in psychiatric disorders exist, including a
study of the DRD2 5′-regulatory region in sib pairs dis-
cordant for schizophrenia (Zhang et al. 2007), a functional
study of the SLC12A6 promoter (Moser et al. 2009), and
a methylation-sensitive representational difference ana-
lysis of lymphoblastoid cells derived from monozygotic
twins noted above (Kuratomi et al. 2008), the report on
BDNF methylation in unipolar depression noted above
(Fuchikami et al. 2011), and the investigation of BD
(D'Addario et al. 2012). Another limitation is that the
approach we used, namely bisulfite conversion-based
analysis, is not able to differentiate 5-methyl cytosine
(5-mC) from 5-hydroxymethyl cytosine (5-hmC) and
unmodified cytosine from 5-formyl cytosine (5-fC) plus
5-carboxylcytosine (5-caC). A final limitation is that
medication effects may be causing false positive results;
we lacked the required current mood stabilizer data to
characterize such potential influences on methylation.
Here, we also report exploratory post hoc results showing
that a majority (4/5) of the FDR-significant methylation
signals from the initial analysis were statistically significant
in rs6265 Val homozygotes (GG) and not in Met car-
riers (AG+AA). Although the findings are not without
some ambiguity, they are suggestive of SNP-methylation
interactions.
Meta-analysis of the original 14 published studies of
rs6265 in BD, including family-based and case–control
designs, showed moderate nominal association for rs6265 -
specifically the G(Val) allele was associated with BD.
Though much evidence points to the rare Met allele having
deleterious cognitive effects, there has been curiosity why
the common Val allele is the one associated with BD
(Fan and Sklar 2008). Our preliminary results in this
small sample, if confirmed by replication, suggest rs6265
SNP-promoter methylation interactions may be measur-
able in BD.Conclusions
The sample size is small and therefore underpowered to
draw firm conclusions. Our results add to a growing lit-
erature on BDNF methylation in BD by the use of pre-
cise mass spectrometry assays of CpGs in previously
uninvestigated BDNF promoters in one of the largest BD
epigenetics samples of peripheral tissue to date; they
underscore the complexity of BDNF regulation across
nine functional promoters and multiple transcripts and
altogether suggest a need for more comprehensive epi-
genetic investigation of the locus.
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